A067290 Stock Overview
JW Shinyak Corporation engages in the production and sale of medicines and medical supplies in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
JW Shinyak Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,720.00 |
| 52 Week High | ₩3,166.67 |
| 52 Week Low | ₩1,716.00 |
| Beta | 0.81 |
| 1 Month Change | -13.87% |
| 3 Month Change | -23.56% |
| 1 Year Change | -41.93% |
| 3 Year Change | -63.60% |
| 5 Year Change | -67.49% |
| Change since IPO | -55.93% |
Recent News & Updates
Recent updates
Is JW Shinyak (KOSDAQ:067290) A Risky Investment?
Mar 04
Factors Income Investors Should Consider Before Adding JW Shinyak Corporation (KOSDAQ:067290) To Their Portfolio
Jan 28Don't Race Out To Buy JW Shinyak Corporation (KOSDAQ:067290) Just Because It's Going Ex-Dividend
Dec 24
What Type Of Returns Would JW Shinyak's(KOSDAQ:067290) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Dec 07Shareholder Returns
| A067290 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -8.1% | -5.0% | -4.3% |
| 1Y | -41.9% | -1.4% | -1.0% |
Return vs Industry: A067290 underperformed the KR Pharmaceuticals industry which returned -1.4% over the past year.
Return vs Market: A067290 underperformed the KR Market which returned -1% over the past year.
Price Volatility
| A067290 volatility | |
|---|---|
| A067290 Average Weekly Movement | 3.9% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A067290's share price has been volatile over the past 3 months.
Volatility Over Time: A067290's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 235 | Yong-Kwan Kim | www.jw-shinyak.co.kr |
JW Shinyak Corporation engages in the production and sale of medicines and medical supplies in South Korea. It offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesity, and other products, as well as eye drops, and antitussives and expectorants. The company also develops prostate cancer treatment, liver cancer treatment, rheumatoid arthritis treatment, etc. using immune cells.
JW Shinyak Corporation Fundamentals Summary
| A067290 fundamental statistics | |
|---|---|
| Market cap | ₩87.19b |
| Earnings (TTM) | -₩37.36b |
| Revenue (TTM) | ₩104.23b |
0.8x
P/S Ratio-2.3x
P/E RatioIs A067290 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A067290 income statement (TTM) | |
|---|---|
| Revenue | ₩104.23b |
| Cost of Revenue | ₩55.55b |
| Gross Profit | ₩48.69b |
| Other Expenses | ₩86.05b |
| Earnings | -₩37.36b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -736.92 |
| Gross Margin | 46.71% |
| Net Profit Margin | -35.84% |
| Debt/Equity Ratio | 173.2% |
How did A067290 perform over the long term?
See historical performance and comparison